SavedAdd your journal

Journals / Çocuk Enfeksiyon Dergisi / 2011 / Cilt: 5 - Sayı: 2

Recent Advances in Pneumococcal Conjugate Vaccines: A 13-Valent Pneumococcal Conjugate Vaccine

Konjuge Pnömokok Aşılarında Son Gelişmeler: 13-Valanlı Konjuge Pnömokok Aşısı

Mehmet CEYHAN
Pages
68–73
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper, data regarding PCV7 immunization and outcomes,as well as the switch from PCV7 to PCV13, were reviewed. (J Pediatr Inf 2011; 5: 68-73)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Streptococcus pneumoniae (pneumococcus) is an important cause of serious infectious diseases, leading to death among children all over the world.
📊
Key Findings & Data:The 7-valent pneumococcal conjugate vaccine (PCV7), which was introduced in 2000 to prevent pneumococcal infections, was included in the Childhood National Immunization Program of Turkey in November 2008 and has been used since then.
💡
Conclusion & Impact:In this paper, data regarding PCV7 immunization and outcomes,as well as the switch from PCV7 to PCV13, were reviewed. (J Pediatr Inf 2011; 5: 68-73)
🔬Design:Review & Systematic Survey
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

Streptococcus pneumoniae (pneumococcus) is an important cause of serious infectious diseases, leading to death among children all over the world. The 7-valent pneumococcal conjugate vaccine (PCV7), which was introduced in 2000 to prevent pneumococcal infections, was included in the Childhood National Immunization Program of Turkey in November 2008 and has been used since then. Data from various regions of the world have shown that the frequency of infections due to serotypes included in the PCV7 has substantially decreased, and these infections have almost been eradicated in some regions with PCV7 vaccination. On the other hand, there is a relative increase in the frequency of infections due to serotypes such as 19A, which are not included in the PCV7. Therefore, many countries, including Turkey, have implemented the 13-valent pneumococcal conjugate vaccine (PCV13) immunization program. In this paper, data regarding PCV7 immunization and outcomes,as well as the switch from PCV7 to PCV13, were reviewed. (J Pediatr Inf 2011; 5: 68-73)

Özet

Streptococcus pneumoniae (pnömokok) tüm dünyada çocuklarda ciddi enfeksiyon hastalıklarına neden olarak ölümlere yol açan önemli bir etkendir. Pnömokok enfeksiyonlarını önlemek üzere 2000 yılında kullanıma sunulan 7 valanlı Konjuge Pnömokok Aşısı (KPA7) aşısı ülkemizde Kasım 2008’den beri ulusal çocuk aşılama takvimine dahil olarak uygulanmaktadır. Dünyanın farklı bölgelerinden gelen veriler KPA7 uygulaması ile bu aşının kapsamına giren serotiplere bağlı olan enfeksiyonların önemli oranlarda azaldığını hatta bazı bölgelerde neredeyse eradike edildiğini göstermektedir. Öte yandan başta 19A serotipi olmak üzere KPA7’de yer almayan serotiplere bağlı enfeksiyonlarda göreceli bir artış görülmektedir. Bu nedenlerle Türkiye dahil birçok ülkede 13 valanlı Konjuge Pnömokok Aşısı (KPA13) uygulamasına geçilmiştir. Bu yazıda KPA7 uygulamasına ve sonuçlarına ilişkin bilgiler ve KPA13’e geçiş konusu gözden geçirilmiştir. (J Pediatr Inf 2011; 5: 68-73)

🔖

Cite This Article

CEYHAN, M. (2011). Recent Advances in Pneumococcal Conjugate Vaccines: A 13-Valent Pneumococcal Conjugate Vaccine. Çocuk Enfeksiyon Dergisi, Cilt: 5 - Sayı: 2, 68–73. https://ajindex.com/articles/212375

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project. PLoS Medicine 2010; 7:e1000348. Ceyhan M. Çocuklarda pnömokok enfeksiyonları ve aşılama. Çocuk Sağlığı ve Hastalıkları Dergisi 2009; 52: 91-9.
  2. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374: 893-902.
  3. McIntosh ED, Fritzell B, Fletcher MA. Burden of paediatric invasive pneumococcal disease in Europe, 2005. Epidemiology and Infection 2007; 135: 644-56.
  4. Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. International Journal of Antimicrobial Agents 2008; 32: 199-206.
  5. Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. Recommendations and Reports / Centers for Disease Control 2010; 59: 1-18. Schranz J. Pneumococcal conjugate vaccines: what do we know and what do we need? Procedia in Vaccinology 2009; 1: 189-205.
  6. Harboe ZB, Valentiner-Branth P, Benfield TL, et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme. Vaccine 2010; 28: 2642-7.
  7. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. The Journal of Infectious Diseases 2010; 201: 32-41.
  8. Durando P, Crovari P, Ansaldi F, et al. Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine 2009; 27: 3459-62.
  9. Guevara M, Barricarte A, Gil-Setas A, et al. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clinica Microbiology and Infection 2009; 15: 1013-9.
  10. Vestrheim DF, Løvoll O, Aaberge IS, et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 2008; 26: 3277-81.
  11. Roche PW, Krause V, Co